Fourteen episodes of acute pseudomonal pulmonary exacerbations of cystic fibrosis were treated with high-dose tobramycin (10.1–17.1 mg/kg/d) and carbenicillin (600 mg/kg/d). The Sawchuck-Zaske method of dosing tobramycin was used and resulted in good agreement between the desired and measured peak (8.1 ± 0.5 vs. 8.2 ± 1.5 μg/ml) and trough (0.5 ± 0.2 vs. 1.0 ± 0.4 μg/ml) concentrations. Ninety-three percent of cases improved clinically. Forced expiratory volume in one second and forced vital capacity increased significantly (39.3 ± 24.8, p < 0.001 and 24.1 ± 22.8 percent, p < 0.05, respectively) after treatment. Pseudomonas aeruginosa was eradicated from the sputa of 69 percent of the cases, with recolonization occurring within three months. Significant nephrotoxicity and ototoxicity were not seen. Liver enzymes, however, were elevated in 29 percent of those treated. Combination high-dose carbenicillin and tobramycin satisfies the treatment goals of bacteriological and clinical cure with a minimal degree of toxicity.
PaporiszU.PosseltHGWönneR., Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease. Eur J Pediatr1979; 130: 259–69.
2.
McLaughlinFJMatthewsW.StriederD., Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis1983; 147: 559–67.
3.
ParryM.NeuH.Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis. J Infect Dis1976; 134 (suppl): 194–7.
4.
ThomsenJ.FriisB.High dosage tobramycin treatment of children with cystic fibrosis. Bacteriologic effect and clinical ototoxicity. Int J Pediatr Otorhinolaryngol1979; 1: 33–40.
5.
RabinHEHartleyFLBryanLEElfringGL. Evaluation of a high dose tobramycin and ticarcillin treatment protocol in cystic fibrosis based on improved susceptibility criteria and antibiotic pharmacokinetics. In: SturgisJM, ed. Perspectives in cystic fibrosis: Proceedings of the Eighth International Cystic Fibrosis Congress. Toronto: Imperial Press, 1980: 370–5.
6.
McCraeWMRaeburnJAHansonEJ. Tobramycin therapy in infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: Effect of dosage and concentration of antibiotic in sputum. J Infect Dis1976; 134: 191–3.
7.
MartinAJSmalleyCAGeorgeGHHealingDEAndersonCM. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis. Arch Dis Child1980; 55: 604–7.
8.
MøllerNEHøibyN.Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Scand J Infect Dis1981; 24 (suppl): 87–91.
9.
FriisB.Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis. Scand J Infect Dis1979; 11: 211–7.
10.
SchofieldDHMangioneRAKayBGGorvoyJD. Lack of aminoglycoside-induced nephrotoxicity in cystic fibrosis (letter). Drug Intell Clin Pharm1984; 18: 153–4.
11.
SawchuckRJZaskeDECipolleRJ., Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther1977; 21: 362–9.
12.
ElenbaasRMElenbaasJKCuddyPG. Evaluating the medical literature, Part II: Statistical analysis. Ann Emerg Med1983; 2: 610–20.
13.
KearnsGLHilmanBCWilsonJT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr1982; 100: 312–8.
14.
KellyHBMenendezR.FanL.MurphyS.Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr1982; 100: 318–21.
15.
BauerLAPiecoroJJWilsonHDBlouinRA. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm1983; 2: 262–4.
16.
FinkelsteinE.HallK.Aminoglycoside clearance in patients with cystic fibrosis. J Pediatr1979; 94: 163–4.
17.
FraserG.GrimesGRValentiAJ. Applied pharmacokinetics in acute exacerbations of Pseudomonas aeruginosa pneumonia in cystic fibrosis (letter). J Pediatr1982; 101: 792.
18.
Cystic fibrosis and Pseudomonas infection. Lancet1983; 2: 257–8.
19.
HøibyN.Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr Scand1982; 301 (suppl): 33–54.
20.
LauWKYoungLSOsherABDooleyRR. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pediatrics1977; 60: 372–7.
21.
WoodREBoatTFDoershukCF. Cystic fibrosis. Am Rev Respir Dis1976; 113: 833–77.
22.
SmithAL. Antibiotic therapy: Efficacy and assessment. In: SturgisJM, ed. Perspectives in cystic fibrosis: Proceedings of the Eighth International Cystic Fibrosis Congress, Toronto: Imperial Press, 1980: 382–8.
23.
MaxwellD.The role of antibiotics given by inhalation in chronic chest disease. J Antimicrob Chemother1983; 11: 203–6.
24.
Hookamp-KorstanjeJaaVan Der LaagJ.Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. J Antimicrob Chemother1983; 12: 175–83.
25.
SturgessJ.ImrieJ.Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol1982; 106: 303–11.
26.
HøibyN.FlensborgEW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand1983; 72: 651–7.
27.
AbramowskyCRSwinehartGL. The nephropathy of cystic fibrosis: A human model of chronic nephrotoxicity. Human Pathol1982; 13: 934–9.
28.
ThomsenJ.FriisB.JensenK.Bak-PedersenK.HildegardLarsen P.Tobramycin ototoxicity. Repeated courses of high dose treatment in children with cystic fibrosis. J Antimicrob Chemother1979; 5: 257–60.
29.
Forman-FrancoB.AbramsonALGorvoyJDSteinT.Cystic fibrosis and hearing loss. Arch Otolaryngol1979; 105: 338–42.
30.
LevyJ.SmithALKoupJR. Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study. J Pediatr1984; 105: 117–24.
